These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The effect of levenogesterol (Norplant) contraception on coagulation as measured by antithrombin-III levels.
    Author: Pryor JA, Cooper KR, Bass JD, Hampton HL, Rock WA, Morrison JC.
    Journal: J Miss State Med Assoc; 1996 Oct; 37(10):777-9. PubMed ID: 8908950.
    Abstract:
    PURPOSE: To determine the effect of contraception given immediately postpartum on coagulation as measured by antithrombin III. STUDY DESIGN: In this prospective study, parturients (n = 85) self selected three means of postpartum contraception: levenorgesterol implants, oral contraceptives, or a barrier method. RESULTS: Baseline coagulation was assessed by antithrombin-III levels in each of the 85 women within 48 hours of delivery (100.35 +/- 1.61%) and at one (109.1 +/- 1.89%) and six (105.51 +/- 1.71%) weeks postpartum. There was a rise in antithrombin-III after delivery but there were no significant differences between the groups. CONCLUSION: The levenorgesterol implant system did not cause a decrease in antithrombin-III in normal parturients. The effect of postpartum Norplant implant use on coagulation factors was investigated in a prospective study conducted in Mississippi, US. 85 postpartum women were given a choice of 3 contraceptive methods: levonorgestrel implants (n = 25), oral contraceptives (n = 38), or a barrier method (n = 22). Antithrombin-III (AT-III) levels were measured on the day of discharge from the hospital after delivery, 7 days after delivery, and 6 weeks after delivery. There was no significant difference between groups in the initial AT-III level (mean, 100.35 +or- 1.61%). At the end of the first postpartum week, AT-III levels rose significantly to 109.1 +or- 1.89%, but again, there were no significant differences according to contraceptive method. By the 6-week follow-up, AT-III levels had stabilized at a mean of 105.51 +or- 1.71%, with no significant between-group differences. AT-III levels in pill users declined more markedly between the first and sixth postpartum weeks than those in the 2 other groups. These findings indicate that subdermal implant use does not affect coagulation, and these devices can be inserted safely during the postpartum period.
    [Abstract] [Full Text] [Related] [New Search]